Visterra raises $30m for infectious disease pipeline
This article was originally published in Scrip
Executive Summary
Visterra raised a $30m Series B round from new and existing venture capital investors to fund clinical development of the company's pipeline of novel monoclonal antibodies to prevent and treat infectious diseases.
You may also be interested in...
IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start
AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.